-       Report 
- October 2025
-  194 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- October 2025
-  182 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- October 2025
-  188 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- October 2025
-  187 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- October 2025
-  191 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
             -       Report 
- October 2025
-  195 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- October 2025
-  188 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- October 2025
-  191 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- October 2025
-  192 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- August 2025
-  193 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
          -       Report 
- October 2025
-  276 Pages 
- Global 
   From       €5206EUR$5,850USD£4,582GBP 
          -       Report 
- October 2025
-  385 Pages 
- Global 
   From       €5206EUR$5,850USD£4,582GBP 
          -       Report 
- October 2025
-  250 Pages 
- Global 
   From       €3995EUR$4,490USD£3,517GBP 
          -       Report 
- June 2025
-  122 Pages 
- Asia Pacific 
   From       €3559EUR$4,000USD£3,133GBP 
            -       Drug Pipelines 
- March 2022
-  900 Pages 
- Global 
   From       €6407EUR$7,200USD£5,640GBP 
      €8009EUR$9,000USD£7,050GBP 
          -       Report 
- November 2022
-  295 Pages 
- Global 
   From       €4405EUR$4,950USD£3,877GBP 
          -       Report 
- September 2023
-  270 Pages 
- Global 
   From       €3715EUR$4,175USD£3,270GBP 
          -       Report 
- March 2019
-  255 Pages 
- Global 
   From       €2202EUR$2,475USD£1,939GBP 
          -       Report 
- February 2024
-  75 Pages 
- Global 
   From       €4405EUR$4,950USD£3,877GBP 
          -       Report 
- November 2023
-  78 Pages 
- Global 
   From       €2180EUR$2,450USD£1,919GBP 
       
      The Tumor Profiling market within the Diagnostics industry is a rapidly growing sector. It involves the use of advanced technologies such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) to analyze the genetic makeup of tumors. This helps to identify the specific mutations that are driving the tumor's growth, allowing for more targeted treatments. Tumor profiling can also be used to monitor the effectiveness of treatments and to detect recurrence of the tumor.
The market is    driven by the increasing prevalence of cancer, the growing demand for personalized medicine, and the development of new technologies. Additionally, the increasing availability of genomic data and the development of artificial intelligence (AI) and machine learning (ML) are expected to further drive the market.
Some of the major companies in the Tumor Profiling market include Illumina, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, and Roche. Show Less   Read more